MCED tests have the potential to identify the presence of cancer for more than one cancer at a time, before signs or symptoms appear. As the tests continue to evolve, check out some of the FAQs below to find the latest information on MCED tests, how they fit into current screening recommendations and more.
MCED tests are designed to be complementary to, not a replacement for, existing screenings, such as mammograms, colonoscopies and Pap tests. MCED can be administered alongside existing screening tests to increase the value of early detection visits. Recommended single-cancer screenings will remain the primary screening for the cancers that have recommended screenings today.
Different MCED tests are being developed and clinical trials are underway. Some tests are available now by prescription through a doctor. MCED tests are not covered by insurance. People who have this test will most likely have to pay for some or all of it out-of-pocket.
Under current law, Medicare coverage of preventive services is limited to tests for which Congress has explicitly authorized coverage. Private insurers cover screening tests that receive an “A” or “B” recommendation from the U.S. Preventive Services Task Force (USPSTF). The Task Force has not yet evaluated MCED tests.
Genetic testing may be an option for those who want more information about their cancer risk. Predictive genetic testing is performed to look for specific changes, called mutations, in a person’s genes before they show signs of a disease. These tests are often done using blood samples, but may be performed using saliva or other tissues. Genetic tests do not detect the absence or presence of cancer. MCED tests use blood samples and are designed to identify the potential presence of cancer for more than one cancer at a time. If a person has a positive MCED test, additional follow-up testing is needed to determine if cancer is actually present.
Multi-cancer early detection tests are a new and innovative way of screening for cancer; as with any breakthrough technology, there are challenges that must be addressed before they can be utilized on a population level.
Some of these challenges:
The Foundation convened a forum in 2021 for patients, providers, advocacy organizations and other stakeholders to engage in a dialogue around emerging technology in cancer prevention and control with a focus on multi-cancer early detection screening tests and remains engaged in ongoing discussions around a patient-centered approach for MCED.